Cargando…
Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
BACKGROUND & AIMS: Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that <50% of patients achieve complete response on standard treatment. Serum B cell-activating factor (BAFF) levels are elevated...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340979/ https://www.ncbi.nlm.nih.gov/pubmed/32671332 http://dx.doi.org/10.1016/j.jhepr.2020.100123 |